Fig. 2: HLA class II infographics of the eight datasets collected in this study.
From: Unraveling the glycosylated immunopeptidome with HLA-Glyco
a Percentage of samples with HLA class II typing information. b Types of the collected mass spectrometry samples (i.e., patient tissues, cell lines, and tumor-infiltrating lymphocytes/TILs). c Cancer types across the collected mass spectrometry samples. d HLA class II alleles (DR, DB, and DQ) across the collected mass spectrometry samples. e Percentage of glycoPSMs, glycopeptides, and glycosylation sites found in GlyGen. f Abundance of the three categories from panel (a) by spectral count of n = 106 biologically independent samples. Gray boxplot values: Bottom whisker: 1, Q1: 1, Median: 1, Q3: 5, Interquartile range: 4, Top whisker: 11, Minimum: 1, Maximum: 13700. Blue boxplot values: Bottom whisker: 1, Q1: 1, Median: 1, Q3: 2, Interquartile range: 1, Top whisker: 3, Minimum: 1, Maximum: 335. Black boxplot values: Bottom whisker: 1, Q1: 1, Median: 1, Q3: 2, Interquartile range: 1, Top whisker: 3, Minimum: 1, Maximum: 501. g Comparison of the identified glycosylation sites with those reported by Malaker et al.9.
